Detailed Information on Publication Record
2021
Target-Specific Magnetic Resonance Imaging of Human Prostate Adenocarcinoma Using NaDyF4-NaGdF4 Core Shell Nanoparticles
DASH, A., B. BLASIAK, Boguslaw TOMANEK, Peter LATTA, FCJM. VAN VEGGEL et. al.Basic information
Original name
Target-Specific Magnetic Resonance Imaging of Human Prostate Adenocarcinoma Using NaDyF4-NaGdF4 Core Shell Nanoparticles
Authors
DASH, A., B. BLASIAK, Boguslaw TOMANEK (616 Poland, belonging to the institution), Peter LATTA (703 Slovakia, guarantor, belonging to the institution) and FCJM. VAN VEGGEL
Edition
ACS APPLIED MATERIALS & INTERFACES, WASHINGTON, AMER CHEMICAL SOC, 2021, 1944-8244
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
20601 Medical engineering
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 10.383
RIV identification code
RIV/00216224:14740/21:00124240
Organization unit
Central European Institute of Technology
UT WoS
000659315800001
Keywords in English
anti-PSMA; MRI; relaxivity; nanoparticle; paramagnetic; dysprosium; gadlinium; EPR
Tags
International impact, Reviewed
Změněno: 9/10/2024 13:04, Ing. Jana Kuchtová
Abstract
V originále
We illustrate the development of NaDyF4-NaGdF4 core-shell nanoparticles (NPs) for targeting prostate cancer cells using a preclinical 9.4 T magnetic resonance imaging (MRI) of live animals. The NPs composed of paramagnetic Dy3+ and Gd3+ (T-2- and T-1-contrast agents, respectively) demonstrate proton relaxivities of r(1) = 20.2 mM(-1) s(-1) and r(2) = 32.3 mM(-1) s(-1) at clinical 3 T and r(1) = 9.4 mM(-1) s(-1) and r(2) = 144.7 mM(-1) s(-1) at preclinical 9.4 T. The corresponding relaxivity values per NP are r(1) = 19.4 x 105 mM(NP)(-1) s(-1) and r(2) = 33.0 x 10(5) mMNP(-1) s(-1) at 3 T and r(1) = 9.0 x 105 mM(NP)(-1) s(-1) and r(2) = 147.0 x 10(5) mM(NP)(-1) s(-1) at 9.4 T. In vivo active targeting of human prostate tumors grown in nude mice revealed docking of anti-prostate-specific membrane antigen (PSMA) antibody-tagged NPs at tumor sites post-24 h of their intravenous injection. On the other hand, in vivo passive targeting showed preferential accumulation of NPs at tumor sites only within 2 h of their injection, ascribed to the enhanced permeation and retention effect of the tumor. A biodistribution study employing the harvested organs of mice, post-24 h injection of NPs, quantified active targeting as nearly twice as efficient as passive targeting. These outcomes provide potential opportunities for noninvasive diagnosis using NaDyF4-NaGdF4 core-shell NPs for target-specific MRI.
Links
| 90129, large research infrastructures |
|